Andrew Artenstein
Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vaccines | 5 | 2015 | 48 | 2.570 |
Why?
| Smallpox Vaccine | 5 | 2013 | 27 | 2.000 |
Why?
| Anthrax | 8 | 2012 | 14 | 1.570 |
Why?
| Communicable Disease Control | 3 | 2015 | 22 | 1.430 |
Why?
| Meningitis, Meningococcal | 2 | 2014 | 8 | 1.140 |
Why?
| Smallpox | 4 | 2009 | 13 | 1.000 |
Why?
| Bioterrorism | 5 | 2008 | 17 | 0.950 |
Why?
| HIV-1 | 15 | 2002 | 571 | 0.930 |
Why?
| Bacterial Toxins | 4 | 2007 | 45 | 0.780 |
Why?
| Military Medicine | 2 | 2009 | 11 | 0.780 |
Why?
| Bacillus anthracis | 4 | 2011 | 12 | 0.740 |
Why?
| Patient Care Team | 2 | 2017 | 188 | 0.730 |
Why?
| Military Personnel | 4 | 2009 | 40 | 0.730 |
Why?
| Mass Vaccination | 2 | 2014 | 2 | 0.730 |
Why?
| Vaccination | 2 | 2015 | 129 | 0.710 |
Why?
| Needles | 2 | 2013 | 40 | 0.710 |
Why?
| Academic Medical Centers | 1 | 2017 | 172 | 0.710 |
Why?
| Humans | 53 | 2017 | 34160 | 0.700 |
Why?
| Virology | 2 | 2013 | 11 | 0.680 |
Why?
| Meningococcal Vaccines | 2 | 2014 | 23 | 0.680 |
Why?
| Length of Stay | 1 | 2017 | 400 | 0.660 |
Why?
| Delivery of Health Care | 1 | 2017 | 162 | 0.660 |
Why?
| HIV Infections | 10 | 2002 | 655 | 0.660 |
Why?
| Teaching Rounds | 1 | 2015 | 5 | 0.650 |
Why?
| Antigens, Bacterial | 3 | 2007 | 161 | 0.650 |
Why?
| Poliomyelitis | 1 | 2014 | 3 | 0.610 |
Why?
| Emergency Service, Hospital | 1 | 2017 | 363 | 0.570 |
Why?
| Disease Outbreaks | 2 | 2012 | 58 | 0.560 |
Why?
| Tobacco Mosaic Virus | 1 | 2012 | 9 | 0.540 |
Why?
| Plant Diseases | 1 | 2012 | 8 | 0.540 |
Why?
| Proprotein Convertases | 1 | 2011 | 3 | 0.530 |
Why?
| Physician's Role | 2 | 2003 | 98 | 0.520 |
Why?
| Sepsis | 1 | 2013 | 139 | 0.520 |
Why?
| Tobacco | 1 | 2012 | 62 | 0.510 |
Why?
| Vaccinia virus | 2 | 2008 | 101 | 0.480 |
Why?
| History, 20th Century | 4 | 2012 | 172 | 0.450 |
Why?
| Communicable Diseases | 2 | 2011 | 55 | 0.440 |
Why?
| Nucleic Acid Amplification Techniques | 3 | 2013 | 17 | 0.410 |
Why?
| Virulence Factors | 2 | 2007 | 55 | 0.400 |
Why?
| RNA, Viral | 4 | 2013 | 196 | 0.390 |
Why?
| Vaccinia | 1 | 2005 | 42 | 0.320 |
Why?
| Chloroquine | 1 | 2004 | 38 | 0.310 |
Why?
| Influenza, Human | 4 | 2013 | 112 | 0.310 |
Why?
| Botulinum Toxins | 1 | 2003 | 7 | 0.290 |
Why?
| Acquired Immunodeficiency Syndrome | 4 | 1997 | 125 | 0.290 |
Why?
| Africa South of the Sahara | 2 | 2014 | 13 | 0.290 |
Why?
| Skin Diseases, Bacterial | 1 | 2003 | 7 | 0.290 |
Why?
| Hospitalization | 2 | 2017 | 637 | 0.260 |
Why?
| Skin | 1 | 2003 | 229 | 0.250 |
Why?
| Immunity, Mucosal | 3 | 1999 | 44 | 0.250 |
Why?
| Polymerase Chain Reaction | 5 | 2012 | 452 | 0.250 |
Why?
| HIV Antibodies | 4 | 1999 | 117 | 0.240 |
Why?
| Anti-Infective Agents | 2 | 2012 | 68 | 0.240 |
Why?
| HIV Envelope Protein gp120 | 5 | 2002 | 116 | 0.240 |
Why?
| DNA Probes | 2 | 2012 | 38 | 0.230 |
Why?
| Influenza A Virus, H5N1 Subtype | 2 | 2011 | 12 | 0.220 |
Why?
| Endotoxins | 2 | 2010 | 59 | 0.220 |
Why?
| History, 19th Century | 2 | 2012 | 48 | 0.210 |
Why?
| History, 21st Century | 2 | 2012 | 83 | 0.210 |
Why?
| Alpha-Globulins | 2 | 2011 | 3 | 0.210 |
Why?
| Patient Dropouts | 1 | 2017 | 39 | 0.190 |
Why?
| Efficiency, Organizational | 1 | 2017 | 56 | 0.190 |
Why?
| Patient Admission | 1 | 2017 | 101 | 0.180 |
Why?
| Virus Diseases | 2 | 2012 | 107 | 0.180 |
Why?
| Influenza A Virus, H3N2 Subtype | 2 | 2013 | 26 | 0.180 |
Why?
| Genes, nef | 1 | 1996 | 6 | 0.180 |
Why?
| Adult | 16 | 2013 | 9698 | 0.180 |
Why?
| Patient Discharge | 1 | 2017 | 214 | 0.170 |
Why?
| Influenza A Virus, H1N1 Subtype | 2 | 2013 | 71 | 0.170 |
Why?
| Tuberculosis, Lymph Node | 1 | 1995 | 2 | 0.170 |
Why?
| Pilot Projects | 2 | 2015 | 497 | 0.160 |
Why?
| Mycobacterium haemophilum | 1 | 1994 | 1 | 0.160 |
Why?
| Mycobacterium Infections | 1 | 1994 | 11 | 0.160 |
Why?
| Poliovirus Vaccines | 1 | 2014 | 2 | 0.150 |
Why?
| Poliovirus | 1 | 2014 | 8 | 0.150 |
Why?
| Cost-Benefit Analysis | 1 | 2015 | 179 | 0.150 |
Why?
| Health Education | 1 | 2015 | 173 | 0.150 |
Why?
| Bacterial Vaccines | 2 | 2010 | 43 | 0.150 |
Why?
| United States | 6 | 2005 | 4021 | 0.150 |
Why?
| Immunomodulation | 1 | 2013 | 13 | 0.150 |
Why?
| Lipopolysaccharides | 3 | 2010 | 516 | 0.150 |
Why?
| International Cooperation | 1 | 2014 | 57 | 0.150 |
Why?
| Drug Industry | 1 | 2014 | 30 | 0.150 |
Why?
| Anti-Bacterial Agents | 3 | 2003 | 382 | 0.150 |
Why?
| Molecular Diagnostic Techniques | 1 | 2013 | 12 | 0.150 |
Why?
| Dacryocystitis | 1 | 1993 | 4 | 0.140 |
Why?
| Tracheal Diseases | 1 | 2013 | 5 | 0.140 |
Why?
| Eye Infections, Bacterial | 1 | 1993 | 3 | 0.140 |
Why?
| Molecular Sequence Data | 9 | 2011 | 2049 | 0.140 |
Why?
| Peptide Fragments | 1 | 1995 | 292 | 0.140 |
Why?
| Bacteriology | 1 | 2012 | 1 | 0.140 |
Why?
| Female | 15 | 2010 | 18881 | 0.140 |
Why?
| Antitoxins | 1 | 2012 | 2 | 0.130 |
Why?
| Phylogeny | 4 | 1998 | 239 | 0.130 |
Why?
| Thailand | 6 | 1999 | 90 | 0.130 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 530 | 0.130 |
Why?
| Viruses | 1 | 2012 | 62 | 0.130 |
Why?
| Hyperlipidemias | 1 | 2011 | 50 | 0.130 |
Why?
| Herpesvirus 1, Cercopithecine | 1 | 1991 | 1 | 0.120 |
Why?
| Research | 1 | 2012 | 138 | 0.120 |
Why?
| Time Factors | 1 | 2017 | 2605 | 0.120 |
Why?
| Veterinary Medicine | 1 | 1991 | 12 | 0.120 |
Why?
| Herpesviridae Infections | 1 | 1991 | 31 | 0.120 |
Why?
| Disaster Planning | 2 | 2008 | 30 | 0.120 |
Why?
| Base Sequence | 5 | 2011 | 1245 | 0.120 |
Why?
| Immunotherapy | 1 | 2012 | 102 | 0.120 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 560 | 0.120 |
Why?
| Spleen | 3 | 2011 | 454 | 0.120 |
Why?
| Cells, Cultured | 2 | 2005 | 1799 | 0.120 |
Why?
| Male | 13 | 2011 | 17242 | 0.120 |
Why?
| Tularemia | 1 | 2010 | 11 | 0.110 |
Why?
| Francisella tularensis | 1 | 2010 | 18 | 0.110 |
Why?
| RNA | 1 | 2012 | 284 | 0.110 |
Why?
| Animals | 9 | 2011 | 14706 | 0.110 |
Why?
| Alzheimer Disease | 1 | 2011 | 216 | 0.110 |
Why?
| Inflammation | 1 | 2013 | 666 | 0.110 |
Why?
| Biological Warfare Agents | 1 | 2008 | 3 | 0.110 |
Why?
| Cyclonic Storms | 1 | 2008 | 3 | 0.110 |
Why?
| Occupational Diseases | 1 | 1991 | 228 | 0.100 |
Why?
| Rescue Work | 1 | 2008 | 11 | 0.100 |
Why?
| Vaccines, Attenuated | 1 | 2008 | 30 | 0.100 |
Why?
| Frail Elderly | 1 | 2008 | 43 | 0.100 |
Why?
| Disaster Medicine | 1 | 2008 | 4 | 0.100 |
Why?
| Survival Analysis | 2 | 2010 | 381 | 0.100 |
Why?
| Diagnosis, Differential | 3 | 2013 | 637 | 0.100 |
Why?
| Macrophages, Peritoneal | 2 | 2005 | 69 | 0.100 |
Why?
| Child | 1 | 2014 | 2648 | 0.090 |
Why?
| Mice, Inbred BALB C | 2 | 2010 | 806 | 0.090 |
Why?
| Young Adult | 1 | 2014 | 2167 | 0.090 |
Why?
| Internal Medicine | 1 | 2008 | 128 | 0.090 |
Why?
| Immunoglobulin A | 3 | 2010 | 41 | 0.090 |
Why?
| Education, Medical, Graduate | 1 | 2008 | 111 | 0.090 |
Why?
| Transcription, Genetic | 1 | 2011 | 786 | 0.090 |
Why?
| Neoplasms | 1 | 2011 | 599 | 0.090 |
Why?
| Furin | 1 | 2005 | 2 | 0.080 |
Why?
| Pericarditis | 1 | 2005 | 6 | 0.080 |
Why?
| Nursing Homes | 1 | 2008 | 282 | 0.080 |
Why?
| History, 18th Century | 1 | 2005 | 10 | 0.080 |
Why?
| Immunoglobulin G | 3 | 2010 | 337 | 0.080 |
Why?
| Neutralization Tests | 1 | 2005 | 122 | 0.080 |
Why?
| Specific Pathogen-Free Organisms | 1 | 2004 | 44 | 0.080 |
Why?
| Leukocyte Count | 1 | 2004 | 81 | 0.080 |
Why?
| Amino Acid Sequence | 6 | 1998 | 1491 | 0.080 |
Why?
| Double-Blind Method | 1 | 2005 | 489 | 0.070 |
Why?
| Antibodies, Viral | 1 | 2005 | 224 | 0.070 |
Why?
| Cell Death | 1 | 2004 | 208 | 0.070 |
Why?
| Biomedical Research | 1 | 2005 | 142 | 0.070 |
Why?
| Soft Tissue Infections | 1 | 2003 | 24 | 0.070 |
Why?
| Mice | 4 | 2011 | 7381 | 0.070 |
Why?
| Rats | 1 | 2007 | 1762 | 0.070 |
Why?
| Cell Survival | 1 | 2004 | 450 | 0.070 |
Why?
| Chronic Disease | 3 | 2013 | 536 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 1 | 2004 | 694 | 0.070 |
Why?
| Neutrophils | 1 | 2004 | 265 | 0.070 |
Why?
| Monocytes | 1 | 2004 | 299 | 0.070 |
Why?
| Botulism | 1 | 2002 | 1 | 0.070 |
Why?
| Education, Medical, Continuing | 1 | 2002 | 94 | 0.060 |
Why?
| Bacterial Infections | 1 | 2002 | 85 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 1997 | 402 | 0.060 |
Why?
| HIV Envelope Protein gp160 | 2 | 1999 | 6 | 0.060 |
Why?
| DNA, Viral | 3 | 1996 | 192 | 0.060 |
Why?
| Cervix Uteri | 2 | 1999 | 43 | 0.060 |
Why?
| Middle Aged | 5 | 2002 | 9874 | 0.060 |
Why?
| Asia | 2 | 1996 | 11 | 0.060 |
Why?
| Internet | 1 | 2003 | 358 | 0.060 |
Why?
| Disease Models, Animal | 1 | 2004 | 1190 | 0.050 |
Why?
| Receptors, CCR5 | 1 | 1999 | 35 | 0.050 |
Why?
| Travel | 2 | 1995 | 20 | 0.050 |
Why?
| Adolescent | 2 | 2005 | 4025 | 0.050 |
Why?
| Sexual Behavior | 2 | 1999 | 141 | 0.050 |
Why?
| Treatment Outcome | 1 | 2005 | 2667 | 0.050 |
Why?
| Aged | 3 | 2008 | 7641 | 0.050 |
Why?
| Nasal Mucosa | 1 | 1997 | 13 | 0.050 |
Why?
| Parotid Gland | 1 | 1997 | 7 | 0.050 |
Why?
| Genitalia, Female | 1 | 1997 | 17 | 0.050 |
Why?
| Immunoglobulin M | 1 | 1997 | 102 | 0.050 |
Why?
| Liver | 2 | 2011 | 542 | 0.050 |
Why?
| Immunoglobulins | 1 | 1997 | 74 | 0.050 |
Why?
| Genes, gag | 1 | 1996 | 11 | 0.050 |
Why?
| Genes, env | 1 | 1996 | 13 | 0.050 |
Why?
| Mosaicism | 1 | 1996 | 20 | 0.050 |
Why?
| Uruguay | 1 | 1995 | 1 | 0.040 |
Why?
| Cambodia | 1 | 1995 | 6 | 0.040 |
Why?
| Viral Envelope Proteins | 1 | 1996 | 82 | 0.040 |
Why?
| Sequence Homology, Amino Acid | 1 | 1996 | 342 | 0.040 |
Why?
| Rifampin | 1 | 1994 | 20 | 0.040 |
Why?
| Ciprofloxacin | 1 | 1994 | 13 | 0.040 |
Why?
| DNA, Ribosomal | 1 | 1994 | 30 | 0.040 |
Why?
| Lymphoma, Non-Hodgkin | 1 | 1994 | 32 | 0.040 |
Why?
| ADP Ribose Transferases | 1 | 1994 | 61 | 0.040 |
Why?
| Escherichia coli Infections | 1 | 1994 | 41 | 0.040 |
Why?
| Abscess | 1 | 1994 | 61 | 0.040 |
Why?
| Cloning, Molecular | 1 | 1995 | 360 | 0.040 |
Why?
| Fatty Acids | 1 | 1994 | 134 | 0.040 |
Why?
| Leukocytes, Mononuclear | 1 | 1995 | 214 | 0.040 |
Why?
| Sequence Analysis, DNA | 1 | 1995 | 308 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 1994 | 344 | 0.040 |
Why?
| Oligonucleotide Probes | 1 | 2013 | 42 | 0.040 |
Why?
| Antibodies, Bacterial | 2 | 2010 | 129 | 0.040 |
Why?
| Dacryocystorhinostomy | 1 | 1993 | 3 | 0.040 |
Why?
| Nasolacrimal Duct | 1 | 1993 | 4 | 0.040 |
Why?
| DNA, Bacterial | 1 | 1994 | 217 | 0.040 |
Why?
| Airway Obstruction | 1 | 2013 | 18 | 0.040 |
Why?
| Spirometry | 1 | 2013 | 40 | 0.040 |
Why?
| Genetic Variation | 1 | 1995 | 255 | 0.040 |
Why?
| DNA, Single-Stranded | 1 | 2013 | 49 | 0.040 |
Why?
| Pulmonary Ventilation | 1 | 2013 | 31 | 0.040 |
Why?
| Bronchoscopy | 1 | 2013 | 38 | 0.040 |
Why?
| Seasons | 1 | 2013 | 95 | 0.040 |
Why?
| Prevalence | 1 | 1995 | 795 | 0.040 |
Why?
| Anaplasmataceae | 1 | 1992 | 1 | 0.030 |
Why?
| Rickettsiaceae Infections | 1 | 1992 | 5 | 0.030 |
Why?
| Arachnid Vectors | 1 | 1992 | 9 | 0.030 |
Why?
| Ticks | 1 | 1992 | 15 | 0.030 |
Why?
| DNA Ligases | 1 | 2012 | 4 | 0.030 |
Why?
| Ligase Chain Reaction | 1 | 2012 | 2 | 0.030 |
Why?
| Aza Compounds | 1 | 2011 | 1 | 0.030 |
Why?
| Fluoroquinolones | 1 | 2011 | 6 | 0.030 |
Why?
| Quinolines | 1 | 2011 | 23 | 0.030 |
Why?
| Diagnostic Imaging | 1 | 2013 | 167 | 0.030 |
Why?
| Algorithms | 1 | 1995 | 633 | 0.030 |
Why?
| Escherichia coli | 1 | 1994 | 557 | 0.030 |
Why?
| Macaca mulatta | 1 | 1991 | 162 | 0.030 |
Why?
| Serum | 1 | 2010 | 26 | 0.030 |
Why?
| Colony Count, Microbial | 1 | 2010 | 48 | 0.030 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 64 | 0.030 |
Why?
| Limulus Test | 1 | 1989 | 1 | 0.030 |
Why?
| Nephelometry and Turbidimetry | 1 | 1989 | 11 | 0.030 |
Why?
| Temperature | 1 | 2011 | 249 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2012 | 323 | 0.030 |
Why?
| Nucleic Acid Conformation | 1 | 2011 | 181 | 0.030 |
Why?
| Aminoglycosides | 1 | 1989 | 14 | 0.030 |
Why?
| Neisseria meningitidis | 1 | 2010 | 79 | 0.030 |
Why?
| HIV Seronegativity | 2 | 1999 | 18 | 0.030 |
Why?
| Louisiana | 1 | 2008 | 13 | 0.030 |
Why?
| Florida | 1 | 2008 | 23 | 0.030 |
Why?
| Hybridization, Genetic | 1 | 2008 | 13 | 0.030 |
Why?
| Molecular Epidemiology | 2 | 1998 | 15 | 0.030 |
Why?
| Competency-Based Education | 1 | 2008 | 16 | 0.020 |
Why?
| Problem-Based Learning | 1 | 2008 | 23 | 0.020 |
Why?
| Patient Simulation | 1 | 2008 | 38 | 0.020 |
Why?
| Thermodynamics | 1 | 2008 | 185 | 0.020 |
Why?
| Lung | 1 | 2010 | 470 | 0.020 |
Why?
| Genotype | 2 | 1999 | 480 | 0.020 |
Why?
| Bacterial Proteins | 1 | 2010 | 564 | 0.020 |
Why?
| Internship and Residency | 1 | 2008 | 353 | 0.020 |
Why?
| Antibody Specificity | 1 | 2002 | 95 | 0.020 |
Why?
| Statistics as Topic | 1 | 2002 | 136 | 0.020 |
Why?
| Risk Factors | 2 | 1999 | 3030 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2008 | 2864 | 0.020 |
Why?
| Needle Sharing | 1 | 1999 | 6 | 0.010 |
Why?
| Malaysia | 1 | 1998 | 2 | 0.010 |
Why?
| Immunoglobulin A, Secretory | 1 | 1999 | 3 | 0.010 |
Why?
| Seroepidemiologic Studies | 1 | 1999 | 17 | 0.010 |
Why?
| Body Fluids | 1 | 1999 | 15 | 0.010 |
Why?
| Genes, MHC Class I | 1 | 1999 | 23 | 0.010 |
Why?
| Vagina | 1 | 1999 | 58 | 0.010 |
Why?
| Korea | 1 | 1997 | 3 | 0.010 |
Why?
| CD4 Lymphocyte Count | 1 | 1997 | 85 | 0.010 |
Why?
| Longitudinal Studies | 1 | 1999 | 693 | 0.010 |
Why?
| Nucleic Acid Heteroduplexes | 1 | 1996 | 13 | 0.010 |
Why?
| Serotyping | 1 | 1996 | 57 | 0.010 |
Why?
| Genes, pol | 1 | 1996 | 2 | 0.010 |
Why?
| HIV Long Terminal Repeat | 1 | 1996 | 16 | 0.010 |
Why?
| Case-Control Studies | 1 | 1999 | 660 | 0.010 |
Why?
| Consensus Sequence | 1 | 1996 | 32 | 0.010 |
Why?
| Africa | 1 | 1996 | 18 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 1996 | 112 | 0.010 |
Why?
| Enhancer Elements, Genetic | 1 | 1996 | 64 | 0.010 |
Why?
| HIV Envelope Protein gp41 | 1 | 1996 | 19 | 0.010 |
Why?
| HIV Seropositivity | 1 | 1996 | 73 | 0.010 |
Why?
| Antigens, CD4 | 1 | 1996 | 123 | 0.010 |
Why?
| O Antigens | 1 | 1994 | 4 | 0.010 |
Why?
| Exotoxins | 1 | 1994 | 5 | 0.010 |
Why?
| Cohort Studies | 1 | 1999 | 1417 | 0.010 |
Why?
| Polysaccharides, Bacterial | 1 | 1994 | 43 | 0.010 |
Why?
| Antibody Formation | 1 | 1994 | 103 | 0.010 |
Why?
| NF-kappa B | 1 | 1996 | 386 | 0.010 |
Why?
| Binding Sites | 1 | 1996 | 749 | 0.010 |
Why?
| Peptides | 1 | 1996 | 418 | 0.010 |
Why?
| Promoter Regions, Genetic | 1 | 1996 | 579 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 1994 | 477 | 0.010 |
Why?
| Prospective Studies | 1 | 1997 | 1668 | 0.010 |
Why?
|
|
Artenstein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|